Skip to main content
Karim Chamie, MD, Urology, Los Angeles, CA

KarimChamieMD

Urology Los Angeles, CA

Surgical Oncology

Professor, Urology, UCLA School of Medicine

Dr. Chamie is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Chamie's full profile

Already have an account?

  • Office

    UCLA Medical Center
    200 Medical Plaza, Suite 140
    Los Angeles, CA 90095
    Phone+1 310-794-2858
    Fax+1 310-794-2858

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Urologic Surgical Oncology, 2011 - 2012
  • Ronald Reagan UCLA Medical Center
    Ronald Reagan UCLA Medical CenterFellowship, Health Services Research, 2010 - 2011
  • UCLA School of Public Health
    UCLA School of Public HealthMSHS, Health Services Research, 2009 - 2010
  • University of California Davis Health
    University of California Davis HealthResidency, Urology, 2005 - 2009
  • University of California Davis Health
    University of California Davis HealthResidency, Surgery, 2003 - 2005
  • Keck School of Medicine of the University of Southern California
    Keck School of Medicine of the University of Southern CaliforniaClass of 2003

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2004 - 2024
  • American Board of Urology Urology

Awards, Honors, & Recognition

  • Research Career Development Award STOP CANCER Research Foundation
  • SEED Grant Phase One Foundation
  • SEED Grant HH Lee Surgical Society

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Radical Prostatectomy Then and Now: Surgical Overtreatment of Prostate Cancer Is Declining from 2009 to 2016 at a Tertiary Referral Center  
    Amirali Salmasi, Izak Faiena, Karim Chamie, Urologic Oncology

Lectures

  • Preliminary phase 2 clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients. 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019

Press Mentions

  • FDA Approval of Anktiva Heralds a New Era in the Treatment of BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
    FDA Approval of Anktiva Heralds a New Era in the Treatment of BCG-Unresponsive Non–Muscle-Invasive Bladder CancerApril 23rd, 2024
  • How Bladder Cancer Immunostimulant N-803 May Shake Things Up
    How Bladder Cancer Immunostimulant N-803 May Shake Things UpApril 20th, 2023
  • AUA 2022: Late-Breaking Plenary Highlights
    AUA 2022: Late-Breaking Plenary HighlightsJuly 27th, 2022
  • Join now to see all

Grant Support

  • Health Disparities in Prostate CancerNIH Loan Repayment Program2012–2016
  • Quality of Care in Patients with Bladder CancerAmerican Cancer Society2009–2011
  • Quality Of Care In Patients With Bladder Cancer.National Cancer Institute2009–2011

Professional Memberships

Other Languages

  • Spanish